Zobrazeno 1 - 10
of 44
pro vyhledávání: '"M A, Bahamondes"'
Autor:
Caitlin R. Williams, M. Valeria Bahamondes, Rodolfo Gómez Ponce de León, Helymar da Costa Machado, Luis Bahamondes, Sonja Caffe, Suzanne Jacob Serruya
Publikováno v:
Sexual and Reproductive Health Matters, Vol 31, Iss 1 (2023)
AbstractPregnancy-related complications are a substantial source of morbidity and mortality among adolescents in low- and middle-income countries. While the youngest adolescents (those aged 10–14) are considered to be at particularly high risk of a
Externí odkaz:
https://doaj.org/article/6ca9e50b7d9f419082be3ad4192af0d9
Autor:
Alice F. Cartwright, Amelia C. L. Mackenzie, Rebecca L. Callahan, M. Valeria Bahamondes, Laneta J. Dorflinger
Publikováno v:
Frontiers in Global Women's Health, Vol 3 (2022)
Externí odkaz:
https://doaj.org/article/2943a9fba3fa4e2a849482cc070ea3bf
Publikováno v:
Revista de otorrinolaringología y cirugía de cabeza y cuello. 81:103-112
Autor:
Luis Bahamondes, M. Valeria Bahamondes
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 100:641-648
The use of intrauterine devices (IUDs), including the copper-bearing device and the levonorgestrel intrauterine system (LNG-IUS), is safe among nulligravidas and adolescent girls. However, several misconceptions limit their use in clinical practice;
Autor:
M. Valeria Bahamondes, Luis Bahamondes
Publikováno v:
Trends in Andrology and Sexual Medicine ISBN: 9783030709310
The use of long-acting reversible contraceptive (LARCs) methods is the best tool to reduce unplanned pregnancy rates, given their superior contraceptive effectiveness which is comparable to that of permanent contraception. Fortunately, LARCs have evo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3e5d5545dcb6eb71c493c1a727542af
https://doi.org/10.1007/978-3-030-70932-7_8
https://doi.org/10.1007/978-3-030-70932-7_8
Autor:
Luis Bahamondes, Cassia Teatin Juliato, Ilza Monteiro, Arlete Fernandes, M. Valeria Bahamondes, Moazzam Ali
Publikováno v:
Contraception. 97:205-209
Objective To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women who maintain the same device without changes after 60 months. Study design
Autor:
Catalina Merino-Osorio, Z Jaime Leppe, M Paz Bahamondes, Juan Alberto Lecaros, T Gustavo Mattar
Publikováno v:
Acta bioethica. 23:47-54
Antecedentes: La investigacion en centros educacionales es una fuente frecuente de estudios de las areas sociales y salud. Objetivo: Determinar el conocimiento y la adherencia a la regulacion etica y legal vigente de la investigacion realizadas con n
Publikováno v:
Best practiceresearch. Clinical obstetricsgynaecology. 66
Unplanned pregnancy (UP) is a public health problem, which affects millions of women worldwide. Providing long-acting reversible contraceptive (LARC) methods is an excellent strategy to avoid or at least reduce UP, because the effectiveness of these
Autor:
M. Valeria Bahamondes, Arundhati Gosavi, Kuldip Singh, Nathalie Kapp, Tamás Bitó, Thi My Huong Nguyen, Luis Bahamondes, Gyorgy Bartfai, Manopchai Thamkhantho, Mario Festin, Ndema Habib
Publikováno v:
Human Reproduction (Oxford, England)
STUDY QUESTION Will the use of levonorgestrel (LNG) 1.5 mg taken at each day of coitus by women who have relatively infrequent sex be an efficacious, safe and acceptable contraceptive method? SUMMARY ANSWER Typical use of LNG 1.5 mg taken pericoitall
Autor:
Estephania Pignaton, Simone Appenzeller, Rafaella C Rebelo, Arlete Fernandes, Luis Bahamondes, M. Valeria Bahamondes, Lilian Tereza Lavras Costallat
Publikováno v:
Archives of gynecology and obstetrics. 299(6)
The disease status and thromboembolic events in women with systemic lupus erythematosus (SLE), with and without anti-phospholipid syndrome (APS), were evaluated before and after placement of the 52-mg levonorgestrel-releasing intrauterine system (LNG